Scott Parry, DO
Internal Medicine · Atlanta, GANPI 1306860101
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,408 of the $162,198 with a category attached, or 79.8%. Viiv Healthcare Company accounts for 74.3% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $61,710 and has fallen 73.2% since, to $16,562 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,314 payments — averaging $123.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$120K
- Gilead$27K
- AbbVie$2K
- Merck$1K
- Novo Nordisk$1K
- Johnson & Johnson$1K
- plus $9K from 54 others
What the payments were for
- Consulting fees$2,4402%
- Speaking & faculty fees$129,40880%
- Travel & lodging$6,0694%
- Food & beverage$24,11115%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,198 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 119 | $361,725 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 70 | $283,151 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 30 | $175,886 |
| MounjaroTirzepatide | 84 | $84,293 |
| DescovyEmtricitabine/Tenofov Alafenam | 33 | $74,436 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $54,468 |
| OzempicSemaglutide | 49 | $53,185 |
| OxycontinOxycodone Hcl | 12 | $39,519 |
| PrezcobixDarunavir/Cobicistat | 11 | $26,521 |
| IsentressRaltegravir Potassium | 13 | $25,296 |
| FarxigaDapagliflozin Propanediol | 25 | $24,036 |
| XareltoRivaroxaban | 20 | $17,933 |
| MyrbetriqMirabegron | 16 | $15,490 |
| JardianceEmpagliflozin | 20 | $14,880 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 11 | $9,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $26,789 | $412,054115 claims |
| Viiv Healthcare CompanyDovato | $120,483 | $361,725119 claims |
| Janssen Products, LPSymtuza | $129 | $175,88630 claims |
| Lilly USA, LLCMounjaro | $355 | $84,29384 claims |
| Novo NordiskOzempic | $1,103 | $53,18549 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $1,030 | $44,45431 claims |
| MerckIsentress | $1,492 | $25,29613 claims |
| AstraZenecaFarxiga | $442 | $24,03625 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $15,49016 claims |
| Boehringer IngelheimJardiance | $264 | $14,88020 claims |
| AbbVieLinzess, Synthroid | $2,084 | $8,02438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Tracey HenryAtlanta$305K
- Jennifer GilliganAtlanta$162K
- Tanna LimAtlanta$88K
- Sally IwamotoAtlanta$60K
- Antoine TrammellAtlanta$33K
- Samuel AdamsAtlanta$30K
- Jamal HajjariAtlanta$29K
- Carlos SaldanaAtlanta$25K
- Michael HicksonAtlanta$22K
- Robert KaufmannAtlanta$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.